In the News January 2, 2018
Total Page:16
File Type:pdf, Size:1020Kb
From: ITNDaily Subject: Mount Sinai In The News - January 2, 2018 Date: Tuesday, January 02, 2018 12:42:24 PM Attachments: ATT00001.txt In the News January 2, 2018 Politico New York – January 2 Have Macrophage, Will Travel — Dan Goldberg Mount Sinai researchers, writing in Nature Communications, say the macrophages that reside in healthy breast tissue surrounding milk ducts play a large role in helping early breast cancer cells travel to other parts of the body. The hope is that these findings could help identify biomarkers in patients at greater risk of carrying metastatic cells. - Icahn School of Medicine at Mount Sinai Learn more: https://www.politico.com/states/new-york/newsletters/politico-new-york-health-care/2018/01/02/dfs-looking-to-help-munis- purchase-health-insurance-020627 Cancer Network – December 30 Could Single-Cell RNA Sequencing Help Personalize Multiple Myeloma Treatment? — Samir Parekh, MD Samir Parekh, MBBS, associate professor of medicine, hematology, medical oncology, and oncological sciences at the Icahn School of Medicine at Mount Sinai, highlights a study that shows that patients with relapsed multiple myeloma may need highly individualized therapy to overcome the complexity of relapsed disease. The researchers found that single-cell RNA sequencing can better characterize patients and potentially improve treatment in a more personalized manner. Results of the study were presented at the 2017 American Society of Hematology Annual Meeting and Exposition in Atlanta. - Samir Parekh, MBBS, Associate Professor, Medicine, Hematology, Medical Oncology, Oncological Sciences, Icahn School of Medicine at Mount Sinai Learn more: http://www.cancernetwork.com/ash-street-team/could-single-cell-rna-sequencing-help-personalize-multiple-myeloma-treatment HFMA: Leadership+ – November 2017 48 Hours To Find A Healthcare Fix – Laura Ramos Hegwer An annual healthcare hackathon at Mount Sinai Health System offers young technology entrepreneurs, computer scientists and engineers, medical and allied healthcare professionals and trainees a forum to seek innovative solutions that improve care. Leaders at Mount Sinai say they developed their health hackathon to cultivate an ecosystem that fosters multi- and transdisciplinary team-based health tech innovation and entrepreneurship. Along with fostering a culture of innovation, the organization seeks to generate new technologies in the hope that some may have commercial potential, said Scott Friedman, MD, dean of therapeutic discovery and chief of liver disease for the Mount Sinai Health System. Mount Sinai differentiates itself from some other organizations that host healthcare hackathons by offering participants a real-life, front-line connection to the challenges of managing patients within an academic healthcare setting. This year’s Health Hackathon theme was cancer, which posed countless opportunities for problem-solving, said Ramon Parsons, MD, PhD, director of the Tisch Cancer Institute at Mount Sinai. “Software tools and devices that would help with patient navigation, disease monitoring, or even securing electronic consent for research studies would be extremely helpful and benefit patients,” he said. - Scott Friedman, MD, Dean, Therapeutic Discovery, Fishberg Professor, Medicine, Professor, Liver Diseases, Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Chief, Liver Diseases, The Mount Sinai Health System - Ramon Parsons, MD, PhD, Director, The Tisch Cancer Institute at Mount Sinai, Professor, Chair, Oncological Sciences, Icahn School of Medicine at Mount Sinai - Peter Backeris, Bioengineer, Icahn School of Medicine at Mount Sinai - Janice Gabrilove, MD, Professor, Oncological Sciences, Icahn School of Medicine at Mount Sinai Learn more: http://www.hfma.org/Leadership/E-Bulletins/2017/November/48_Hours_to_Find_a_Healthcare_Fix/ Daily Nurse – December 29 Mount Sinai Beth Israel Receives Nursing Workforce Diversity Grant — Christina Morgan The Philips School of Nursing (PSON) at Mount Sinai Beth Israel recently received a Nursing Workforce Diversity grant of $800,000 from the US Health Resources and Services Administration (HRSA). The four-year HRSA grant is intended to help increase access to nursing education for students from diverse backgrounds. Carleen Graham, MSN, RN, program coordinator, Philips School of Nursing at Mount Sinai Beth Israel, will serve as program director for WIN, which will follow 21 students from entry to graduation throughout the grant period. “It is an honor to be given such an amazing opportunity and responsibility. It is not only important to our school; it is important to our future nurses and the communities they will serve. This grant will help to address the shortage of nurses from underrepresented groups in New York City – considered to be one of the most diverse cities in the country. We are extremely excited to begin work on this important initiative,” said Graham. - Carleen Graham, MSN, RN, Program Coordinator, Philips School of Nursing at Mount Sinai Beth Israel Learn more: http://dailynurse.com/mount-sinai-beth-israel-receives-nursing-workforce-diversity-grant/ Medpage Today – December 28 Sham Controls In Device Trials Gain Favor After ORBITA — Crystal Phend The ORBITA trial earned a place in the halls of cardiology fame (or infamy, depending on one's view) when it reported that percutaneous coronary intervention (PCI) was no better than a sham procedure for stable angina. But one of the key messages, observed by many, was not the clinical impact -- which it is sure to have -- but that sham procedures can, and perhaps should, be done in PCI trials. Roxana Mehran, MD, professor of medicine, cardiology, population health and policy, director of the interventional cardiovascular research and clinical trials and the Zena and Michael A. Weiner Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai, while a critic of the trial, argued that the focus should be on "the importance of this trial, which was to show that a controlled, placebo procedure is actually possible when we are questioning the need for procedure." - Roxana Mehran, MD, Professor, Medicine, Cardiology, Population Health Science and Policy, Director, Interventional Cardiovascular Research and Clinical Trials, Zena and Michael A. Weiner Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Learn more: https://www.medpagetoday.com/cardiology/pci/70157 Healio – December 14 Pathologic Complete Response May Be Strong Surrogate Endpoint For Breast Cancer Survival Charles Shapiro, MD, director of cancer survivorship and translational breast cancer research at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, offers a perspective on the above referenced study: “For a long time, we knew that pathologic complete response rate was a good endpoint, meaning that the higher the pathologic complete response rate with neoadjuvant therapy, the better patients did. What we didn’t know was whether it correlated with long-term favorable outcomes like EFS and distant RFS. The question was: Did achieving a pathologic complete response mean anything for long-term clinical outcomes? This trial was ideally suited to answer this question. What researchers showed was that, indeed, complete pathologic response rate is a surrogate for EFS and distant RFS. It can’t yet be inferred that it can be surrogate for OS, but it stands to reason that it will.” - Charles Shapiro, MD, Director, Cancer Survivorship, Translational Breast Cancer Research, The Tisch Cancer Institute, Professor, Medicine, Icahn School of Medicine at Mount Sinai Learn more: https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7Bef518d49-a55c-4727-b19d- b383ad1e2859%7D/pathologic-complete-response-may-be-strong-surrogate-endpoint-for-breast-cancer-survival The New York Times – December 29 Does a ‘Strong’ Immune System Ward Off Colds and Flu? — Karen Weintraub “What makes people sick is a combination of bad luck — exposures to viruses or other pathogens — and the state of their immune system,” said Talia Swartz, MD, PhD, assistant professor of medicine and infectious diseases at the Icahn School of Medicine at Mount Sinai.” Someone with a weakened immune system is likely to be more vulnerable to passing bugs than someone with a healthy one.” There are definitely different types of patients who are more resistant to infections or who have slower progression of infectious diseases based on certain immune features we recognize that make them have a stronger immune system. “Frequent hand washing is crucial for keeping bugs from entering the mouth, nose and eyes, where they can spread infections,” added Dr. Swartz. She also recommended annual flu shots to attempt to prevent flu or reduce its severity. Other vaccinations, like the new shingles one, which is now recommended for people 50 and older, are also a good idea to help the immune system. - Talia Swartz, MD, PhD, Assistant Professor, Medicine, Infectious Diseases, Icahn School of Medicine at Mount Sinai Learn more: https://www.nytimes.com/2017/12/29/well/live/does-a-strong-immune-system-ward-off-colds-and-flu.html The New York Times – December 31 Fire Department Finds A Way Around Times Square Traffic For Medical Emergencies — Jan Ransom An ambulance, with its siren wailing and lights flashing, was unable to move, stuck in gridlocked traffic one recent afternoon along Eighth Avenue in Times Square. Some drivers tried to get out of the way even as pedestrians hurried past. But it was too late. The